EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Lorlatinib and Amivantamab: A Paradigm Shift in EGFR and ALK Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making

Paolo Maione, Valentina Palma, Cesare Gridelli

Oncology Research · 2026

DOI: 10.32604/or.2026.072992 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Research, 2026. Verfasst von Paolo Maione und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, S.G. Moscati Hospital, Avellino, 83100, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase, Lung Neoplasms, Lactams, Macrocyclic. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma KinaseLung NeoplasmsLactams, MacrocyclicAntineoplastic Combined Chemotherapy ProtocolsHumansErbB ReceptorsAminopyridinesProtein Kinase InhibitorsLactamsPyrazolesDecision Making

Stichwörter der Autor:innen

Non-small cell lung canceralectinibamivantamabbrigatiniblorlatinibosimertinibshared-decision making

Substanzen

lorlatinibAnaplastic Lymphoma KinaseErbB ReceptorsAminopyridinesALK protein, humanLactams, MacrocyclicProtein Kinase InhibitorsLactamsPyrazolesEGFR protein, human

Autor:innen und Institutionen

  • Division of Medical Oncology, S.G. Moscati Hospital, Avellino, 83100, Italy.
  • Division of Medical Oncology, Università degli Studi della Campania "Luigi Vanvitelli", Napoli, 80121, Italy.

Zitieren

APA

Maione, P., Palma, V., & Gridelli, C. (2026). Lorlatinib and Amivantamab: A Paradigm Shift in EGFR and ALK Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making. Oncology Research. https://doi.org/10.32604/or.2026.072992

Vancouver

Maione P, Palma V, Gridelli C. Lorlatinib and Amivantamab: A Paradigm Shift in EGFR and ALK Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making. Oncology Research. 2026. doi:10.32604/or.2026.072992

BibTeX
@article{Maione2026,
  author = {Maione, Paolo and Palma, Valentina and Gridelli, Cesare},
  title = {Lorlatinib and Amivantamab: A Paradigm Shift in EGFR and ALK Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making},
  journal = {Oncology Research},
  year = {2026},
  doi = {10.32604/or.2026.072992}
}
Kostenlos starten →